Oxford BioMedica received a buy rating and price target from Jefferies Financial Group, with ratings aggregated by MarketBeat.
2 reports, 1 independent
Updated Sep 4
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Oxford BioMedica received a buy rating and price target from Jefferies Financial Group, with ratings aggregated by MarketBeat.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Oxford BioMedica
bioTech Company
Nothing else this week.
-
Jefferies Financial Group
American financial services company
Related events
- MarketBeat aggregated stock performance data for Adicet Bio, Inc., which trades on Nasdaq, while Jefferies Financial Group issued a rating and price objective.
- MarketBeat provided consensus ratings and target prices, while Jefferies Financial Group reaffirmed a hold rating on Target Healthcare REIT.
- Analyst rating targets are increasing across the market, with data aggregated by various financial firms including FactSet and MarketBeat.
- Analyst firms provided ratings and price targets for Anglo American plc.
- Jefferies Financial Group reaffirmed a 'buy' rating and issued a $45.00 target price for NewAmsterdam Pharma, Inc.